A Phase 2, Enriched-enrollment, Randomized-withdrawal, Double-blinded, Placebo-Controlled Study to Assess the Efficacy, Tolerability, and Safety of Intranasal Oxytocin in Subjects With Chronic Migraine
Phase of Trial: Phase II
Latest Information Update: 19 May 2016
Price : $35 *
At a glance
- Drugs Oxytocin (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Sponsors Trigemina
- 11 May 2016 Status changed from active, no longer recruiting to completed.
- 28 Oct 2015 Planned End Date changed from 1 Aug 2015 to 1 Jan 2016 as per ClinicalTrials.gov record.
- 28 Oct 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Oct 2015 as per ClinicalTrials.gov record.